Moore Capital Management’s Repligen RGEN Stock Holding History

Moore Capital Management’s Portfolio RGEN Stock Details RGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-8,000	Closed	-$1.07M	–	797
2025 Q3	$1.07M	Buy	+8,000	New	+$972K	0.01%	409

Other funds holding RGEN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Moore Capital Management's RGEN Position: Q1 2026 in Review

Moore Capital Management sold out of Repligen (RGEN) in Q1 2026, closing a stake of 150,000 shares — an estimated $24.6M sold.

Moore Capital Management first reported a position in RGEN in Q3 2023 and held it in 5 quarters. The position peaked at $24.6M in Q4 2025. 441 funds tracked by Wall St. Rank hold RGEN as of Q1 2026.

Moore Capital Management reported no remaining Repligen position as of Q1 2026 after selling out during the quarter.
Moore Capital Management sold 150,000 Repligen shares in Q1 2026, an estimated $24.6M.
Moore Capital Management first reported a position in Repligen in Q3 2023 and held it in 5 quarters.
Moore Capital Management's Repligen position peaked at $24.6M in Q4 2025.
441 funds tracked by Wall St. Rank held Repligen as of Q1 2026.

Based on Moore Capital Management's 13F filing for Q1 2026, filed 15 May 2026.